New hope for Tough-to-Treat hodgkin lymphoma: immune drug combo trial shows promise
NCT ID NCT03016871
Summary
This study is testing a two-part treatment for Hodgkin lymphoma that has come back or stopped responding to initial therapy. It combines an immunotherapy drug (nivolumab) that helps the immune system fight cancer with a standard chemotherapy regimen. The goal is to control the cancer well enough so patients can successfully receive a stem cell transplant, a potentially curative next step.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
-
Fred Hutchinson Cancer Research Center
Seattle, Washington, 98109, United States
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
-
Yale University
New Haven, Connecticut, 06520, United States
Conditions
Explore the condition pages connected to this study.